GlassScriptPhysician profile
George Barboza
NPI 1891436630
$7,272.66
in general payments reported to CMS, 2019-2025
45 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,202 · 2023: $2,679 · 2024: $3,260 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,070.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $954.51 | 2022-2024 | |
| Lilly USA, LLC | $678.63 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $464.88 | 2022-2024 | |
| Amgen INC. | $462.18 | 2022-2024 | Otezla, Repatha, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $415.89 | 2022-2024 | Tradjenta, Jardiance |
| Glaxosmithkline, LLC. | $412.13 | 2022-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $385.01 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $371.26 | 2022-2025 | Rexulti, Nuedexta |
| Astrazeneca Pharmaceuticals LP | $353.29 | 2022-2024 | Breztri, Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $291.94 | 2023-2024 | Xifaxan |
| Esperion Therapeutics, INC. | $263.43 | 2022-2024 | Nexletol |
| Novo Nordisk INC | $227.21 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $224.57 | 2022-2024 | Glassia |
| Radius Health, INC. | $174.10 | 2024 | |
| Phathom Pharmaceuticals, INC. | $165.14 | 2024 | Voquezna |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $143.71 | 2022-2024 | Prolastin-C Liquid |
| Abbott Laboratories | $124.89 | 2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $108.48 | 2023-2024 | Verquvo |
| Astellas Pharma US INC | $101.66 | 2022-2024 | Veozah |
| Neurocrine Biosciences, INC. | $82.98 | 2024 | Ingrezza |
| Pfizer INC. | $79.84 | 2022-2024 | |
| Xeris Pharmaceuticals, INC. | $71.90 | 2022-2024 | Gvoke Hypopen |
| Smith+Nephew, INC. | $64.77 | 2025 | Pico, Collagenase Santyl |
| Ironwood Pharmaceuticals, INC | $64.14 | 2023-2024 | Linzess |
| Mannkind Corporation | $63.78 | 2023 | Afrezza |
| Idorsia Pharmaceuticals US INC | $56.86 | 2023-2024 | Quviviq |
| Dexcom, INC. | $44.82 | 2024-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $40.05 | 2023 | Omnipod |
| Mdd US Operations, LLC | $37.22 | 2024 | Gocovri |
| Lundbeck LLC | $34.80 | 2023-2024 | Rexulti |
| Tanabe Pharma America, INC. | $32.65 | 2024 | |
| Edwards Lifesciences Corporation | $26.12 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Exact Sciences Corporation | $25.21 | 2024 | Cologuard Collection Kit |
| Csl Behring | $24.26 | 2024 | Haegarda |
| Si-Bone, INC. | $21.57 | 2023 | |
| Antares Pharma, INC. | $21.36 | 2023 | Nocdurna, Tlando, Xyosted |
| Corcept Therapeutics | $21.01 | 2022 | |
| Azurity Pharmaceuticals, INC. | $20.87 | 2023 | Edarbi |
| Mylan Specialty L.P. | $20.75 | 2022 | |
| Vertos Medical, INC. | $17.62 | 2024 | Mild Device Kit |
| Tactile Systems Technology INC | $16.60 | 2022 | |
| Cequr Corporation | $15.99 | 2024 | Cequr Simplicity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.67 | 2024 | Caplyta |
| Sumitomo Pharma America, INC. | $15.17 | 2024 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $13.74 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Barboza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.